Balchem (BCPC)
Nasdaq Market Closed
Balchem Corporation is a specialty ingredients company that develops, manufactures and markets products used in nutrition, health, food, animal feed and industrial applications. Rather than competing as a bulk commodity supplier, the company focuses on performance ingredients where formulation expertise, delivery technology and regulatory knowledge are important to customers.
Its largest business is Human Nutrition and Health, which supplies ingredients for food, beverage, dietary supplement and pharmaceutical-related markets. This includes choline nutrients, mineral amino acid chelates and other value-added nutritional systems designed to improve product functionality, stability or health positioning. Balchem is also known for microencapsulation technology, which can protect sensitive ingredients, control release, mask taste or improve handling in finished products.
The Animal Nutrition and Health segment applies similar science to livestock, companion animal and feed markets. Products include choline chloride and chelated minerals, as well as encapsulated nutrients intended to support animal health, productivity and feed efficiency. These offerings serve agricultural customers that need consistent nutrient delivery and specialised formulations.
Balchem’s Specialty Products segment is smaller but distinct, involving the repackaging and distribution of selected gases and chemicals for industrial, medical sterilisation and other technical uses. The company sells mainly in the United States, while also serving international markets.
For investors, BCPC is a specialty chemicals and nutrition stock with exposure to consumer health trends, food innovation and animal agriculture. Its competitive position is supported by ingredient know-how, proprietary processing capabilities and long-standing relationships with manufacturers that require reliable, high-specification inputs.
Last updated
- Market Cap
- 5.14B
- P/E
- 32.5
- P/FCF
- 29.2
- P/S
- 4.86
- Enterprise Value
- 5.26B
- Sector
- —
- Industry
- —
- Address
- 5 PARAGON DRIVE, MONTVALE, NJ, 07645
Balchem Corporation to Participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026
Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2025 Financial Results on February 20, 2026
Balchem Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025
Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025
[Latest] Global Magnesium Supplements Market Size/Share Worth USD 8.94 Billion by 2034 at a 7.43% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Balchem Corporation to Present at the Wells Fargo Industrials and Materials Conference on June 11, 2025
Balchem Corporation Announces Quarterly Conference Call for First Quarter 2025 Financial Results on April 24, 2025
Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025
Balchem Corporation to Present at CJS Securities New Ideas for the New Year Virtual Conference on January 14, 2025
What the $24.07 Billion Microencapsulation Market Means for Industries - Future Insights
Balchem Corporation to Present at Baird’s 54th Annual Global Industrial Conference on November 13, 2024
Balchem Corporation Reports Third Quarter 2024 Financial Results
Chelated Micronutrient Fertilizer Market is Projected to Grow at a 8.6% CAGR through 2034 | Fact.MR Report
Balchem Corporation to Present at the HC Wainwright & Co. 26th Annual Global Investment Conference on September 9, 2024
Global Cattle Nutrition Market Share Projected to Reach an Unprecedented USD 27 Billion Milestone by 2034, Driven by an Average 5.9% CAGR | Future Market Insights, Inc.
Balchem Corporation to Present at the CJS Securities 24th Annual New Ideas Summer Conference on July 10, 2024
Do Options Traders Know Something About Balchem (BCPC) Stock We Don't?
Balchem Corporation to Attend the Deutsche Bank Global Consumer Conference on June 4, 2024
Balchem Corporation Reports First Quarter 2024 Financial Results
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 5.14B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 5.26B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 32.5
- P/B
P/B ratio compares a company's share price to its book value per share.
- 4
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 4.86
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 20.14
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 4.97
- EPS
- 4.92
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.6%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 29.2
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 23.34
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 175.98M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 12.3%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 9.33%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.15
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.55
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.59
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.48
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 209.84K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 159.91
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 270.71M | 263.62M | 267.56M | 255.47M | 250.52M |
| Gross profit | 101.08M | 93.9M | 95.45M | 93.11M | 88.17M |
| Operating income | 55.63M | 52.29M | 54.58M | 51.44M | 51.02M |
| EBITDA | 68.12M | 64.01M | 66.13M | 62.85M | 62.03M |
| Net income | 40.29M | 39.23M | 40.29M | 38.28M | 37.05M |
| Basic EPS | 1.26 | 1.23 | 1.25 | 1.18 | 1.14 |
| Diluted EPS | 1.25 | 1.21 | 1.24 | 1.17 | 1.13 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 1.69B | 1.69B | 1.66B | 1.68B | 1.62B |
| Total liabilities | 408.63M | 428.84M | 363.17M | 410.33M | 408.85M |
| Total equity | 1.29B | 1.26B | 1.3B | 1.27B | 1.21B |
| Cash & equivalents | 72.87M | 74.57M | 65.09M | 65.43M | 49.9M |
| Current assets | 388.94M | 365.61M | 343.72M | 364.86M | 340.24M |
| Current liabilities | 152.54M | 176.38M | 126.37M | 138.14M | 139.56M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 40.06M | 67.28M | 65.57M | 47.25M | 36.46M |
| Investing cash flow | -6.29M | -16.42M | -14.94M | -6.62M | -5.91M |
| Financing cash flow | -34.78M | -41.25M | -50.83M | -28.76M | -31.97M |
| Change in cash | -1.7M | 9.48M | -334K | 15.53M | 386K |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G — BALCHEM CORP | View Filing | |
| edgar index | SCHEDULE 13G — BALCHEM CORP | View Filing | |
| edgar index | DEF 14A — BALCHEM CORP | View Filing | |
| edgar index | DEFA14A — BALCHEM CORP | View Filing | |
| edgar index | 3 — BALCHEM CORP | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| form 3 | Form 3 — Gilson Erin Leigh | View Filing | |
| edgar index | SCHEDULE 13G/A — BALCHEM CORP | View Filing | |
| edgar index | 8-K — BALCHEM CORP | View Filing | |
| edgar index | 10-K — BALCHEM CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — BALCHEM CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| edgar index | 4 — BALCHEM CORP | View Filing | |
| form 4 | Form 4 — Bengtsson Carl Martin | View Filing | |
| form 4 | Form 4 — Miyata Hatsuki | View Filing | |
| form 4 | Form 4 — Tignor Michael Brent | View Filing | |
| form 4 | Form 4 — Boned Frederic | View Filing | |
| form 4 | Form 4 — Backus William A. | View Filing | |
| form 4 | Form 4 — Harris Theodore L | View Filing | |
| form 4 | Form 4 — Reid Martin Luther | View Filing | |
| form 4 | Form 4 — van Gunsteren Job Leonard | View Filing | |
| form 4 | Form 4 — Fischer David B | View Filing | |
| form 4 | Form 4 — Fish Kathleen B | View Filing | |
| form 4 | Form 4 — Knutson Daniel E | View Filing | |
| form 4 | Form 4 — Rigaud Olivier | View Filing | |
| form 4 | Form 4 — VICENTE MONICA | View Filing | |
| form 4 | Form 4 — Wineinger Matthew David | View Filing | |
| form 4 | Form 4 — Bengtsson Carl Martin | View Filing | |
| form 4 | Form 4 — Bengtsson Carl Martin | View Filing | |
| form 4 | Form 4 — Bengtsson Carl Martin | View Filing | |
| form 4 | Form 4 — Bengtsson Carl Martin | View Filing | |
| form 4 | Form 4 — Bengtsson Carl Martin | View Filing | |
| form 4 | Form 4 — Miyata Hatsuki | View Filing | |
| form 4 | Form 4 — Miyata Hatsuki | View Filing | |
| form 4 | Form 4 — Miyata Hatsuki | View Filing | |
| form 4 | Form 4 — Miyata Hatsuki | View Filing | |
| form 4 | Form 4 — Miyata Hatsuki | View Filing | |
| form 4 | Form 4 — Tignor Michael Brent | View Filing | |
| form 4 | Form 4 — Tignor Michael Brent | View Filing | |
| form 4 | Form 4 — Tignor Michael Brent | View Filing | |
| form 4 | Form 4 — Tignor Michael Brent | View Filing | |
| form 4 | Form 4 — Tignor Michael Brent | View Filing | |
| form 4 | Form 4 — Boned Frederic | View Filing | |
| form 4 | Form 4 — Boned Frederic | View Filing | |
| form 4 | Form 4 — Boned Frederic | View Filing | |
| form 4 | Form 4 — Boned Frederic | View Filing | |
| form 4 | Form 4 — Boned Frederic | View Filing | |
| form 4 | Form 4 — Backus William A. | View Filing | |
| form 4 | Form 4 — Backus William A. | View Filing |